Back to top
more

Zimmer Biomet (ZBH)

(Delayed Data from NYSE)

$111.29 USD

111.29
1,399,352

+0.65 (0.59%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $111.30 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.

What's in Store for Intuitive Surgical's (ISRG) Q1 Earnings?

by Zacks Equity Research

Intuitive Surgical's (ISRG) first-quarter earnings are likely to reflect solid performance at Instruments & Accessories segment.

Zimmer Biomet (ZBH) Enhances ZBEdge Portfolio With Latest Suite

by Zacks Equity Research

Zimmer Biomet's (ZBH) latest portfolio enhancement is aimed at improving patient outcome throughout the entire treatment process.

Zimmer Biomet (ZBH) Shows Strong Core Growth Amid Weak EMEA

by Zacks Equity Research

For Zimmer Biomet (ZBH), the spin-off is an important step forward to its transition into a more streamlined business with a focus on more optimized resource allocation.

Why Is Zimmer (ZBH) Down 1.4% Since Last Earnings Report?

by Zacks Equity Research

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zimmer (ZBH) Non-Core Arm Spinoff to Aid Amid COVID-19 Crisis

by Zacks Equity Research

In the Americas, there is increased pressure on Zimmer Biomet (ZBH) procedural volume as a result of surge in infections.

Zimmer Biomet (ZBH) Beats on Q4 Earnings, to Rejig Portfolio

by Zacks Equity Research

Zimmer Biomet (ZBH) states that continued pressure from the COVID-19 pandemic slowed the recovery of elective procedures in the fourth quarter.

Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 2.43% and 0.57%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet's (ZBH) patient volumes are expected to have increased significantly in the fourth quarter due to pent-up demand.

Zimmer Biomet (ZBH) Shows Strong APAC Recovery, EMEA Slow

by Zacks Equity Research

Zimmer Biomet (ZBH) is performing well in its priority areas like quality remediation, supply recovery efforts and product introductions.

Zimmer Biomet (ZBH) Shows Strong Recovery Amid COVID-19 Woes

by Zacks Equity Research

Owing to lack of clarity around the scope and duration of the coronavirus pandemic, Zimmer Biomet (ZBH) is unable to gauge the impact on its overall business in 2020.

Zimmer Biomet (ZBH), HSS Partner to Advance Remote Patient Care

by Zacks Equity Research

Zimmer Biomet's (ZBH) mymobility with Apple Watch platform aids in transforming virtual patient care via the latest partnership with HSS.

Should Value Investors Now Choose Zimmer Biomet (ZBH) Stock?

by Zacks Equity Research

Let's see if Zimmer Biomet (ZBH) stock is a good choice for value-oriented investors right now from multiple angles.

Here's Why You Should Hold on to Globus Medical (GMED) for Now

by Zacks Equity Research

Investors continue to be optimistic about Globus Medical (GMED) on robust product uptake and prominent sales trend improvement in the third quarter.

Zimmer (ZBH) Up 7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zimmer Biomet (ZBH) Boosts Portfolio With A&E Medical Buyout

by Zacks Equity Research

This latest development aligns with Zimmer Biomet's (ZBH) active portfolio management strategy and the ongoing transformation of business aimed at long-term growth.

Globus Medical (GMED) Hits a 52-Week High: What's Driving It?

by Zacks Equity Research

Globus Medical (GMED) is optimistic about maintaining robust product portfolio along with strength in its domestic spine business.

Trina Mukherjee headshot

3 Stocks to Capitalize on Promising Medical Products Industry

by Trina Mukherjee

Despite the challenges triggered by the COVID-19 pandemic, higher demand for IVD products, digital influence and AI & Robotics are likely to lend support to the Zacks Medical - Products industry. ABT, BAX and RMD are well positioned to gain from the prospects.

Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Contracts

by Zacks Equity Research

Zimmer Biomet (ZBH) registers stronger-than-expected recovery of elective procedures in the third quarter.

Zimmer Biomet (ZBH) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 72.38% and 12.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Stock Earnings on Nov 6: ZBH, HRC and HMSY

by Urmimala Biswas

Several medical product stocks have come up with bullish earnings reports so far this reporting cycle. Let's see how ZBH, HRC and HMS are poised ahead of their announcements.

Should You Buy Zimmer Biomet (ZBH) Ahead of Earnings?

by Zacks Equity Research

Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Trina Mukherjee headshot

3 Medical Product Stocks Poised to Beat This Earnings Season

by Trina Mukherjee

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, on the back of several factors.

Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet's (ZBH) Dental product volumes are expected to have declined significantly in the third quarter due to the extremely elective nature of the products.

Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal first-quarter results are likely to reflect solid performance in Pharmaceutical segment.

What's in Store for Becton, Dickinson's (BDX) Q4 Earnings?

by Zacks Equity Research

Becton, Dickinson's (BDX) fiscal fourth-quarter results likely to reflect robust performance at BD Life Sciences.